International workshop to discuss mechanisms of epilepsy
CombiGene’s founder to lead workshop and talk about the work behind CombiGene
From March 4 to 9, the workshop “Jasper’s Basic Mechanisms of the Epilepsies” will be held in Yosemite National Park, California, USA. The international workshop is being arranged for the fifth time and this year, Professor Merab Kokaia, one of CombiGene’s scientific founders, will be among the participants.
Professor Kokaia will lead the workshop “Gene-guided and targeted therapies” and will also present his research and CombiGene’s gene therapy project CG01 as part of a workshop dealing with new therapeutic strategies.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.